SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 or 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Report on Form 6-K dated January 31, 2008

(Commission File No. 1-15024)

 

 

Novartis AG

(Name of Registrant)

 

Lichtstrasse 35

4056 Basel

Switzerland

(Address of Principal Executive Offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F:x       Form 40-F: o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes:o      No:  x

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes: o      No:  x

 

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes: o      No:  x

 

 

		Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com
- Investor Relations Release -

 

Novartis files its Form 20-F annual report with the US Securities and Exchange Commission

 

Basel, January 31, 2008 – Novartis has filed its annual report on Form 20-F with the US Securities and Exchange Commission and has posted this document on its website at www.novartis.com. A copy of the Group’s traditional annual report is also available on this website.  Novartis shareholders may receive a hard copy of either of these documents, each of which contain complete audited financial statements, free of charge, upon request.

 

# # #

 

Novartis Media Relations

 

John Gilardi Novartis Global Media Relations +41 61 324 3018 (direct) +41 79 596 1408 (mobile) john.gilardi@novartis.com

Brandi Robinson Novartis US Corporate Communications +1 212 830 2408 (direct) +1 212 361 9368 (mobile) brandi.robinson@novartis.com

 

e-mail: media.relations@novartis.com

 

Novartis Investor Relations

 

International		North America
Ruth Metzler-Arnold Katharina Ambuehl Pierre-Michel Bringer Jason Hannon Thomas Hungerbuehler Richard Jarvis Isabella Zinck Central phone no:  +41 61 324 7944 e-mail: investor.relations@novartis.com		Jill Pozarek                                           +1 212 830 2445 Edwin Valeriano                                   +1 212 830 2456             e-mail: investor.relations@novartis.com

 

2

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

		Novartis AG
Date:  January 31, 2008		By:	/s/ MALCOLM B. CHEETHAM
		Name:		Malcolm B. Cheetham
		Title:		Head Group Financial
				Reporting and Accounting

 

3